Colombian consensus for the follow-up of patients with Duchenne muscular dystrophy
Article Sidebar
Main Article Content
Abstract
Duchenne muscular dystrophy (DMD) is the most common myopathy in children, X-linked recessive disease, caused by mutations in the DMD gene (Xp21.2). It is characterized by progressive muscular atrophy and weakness, with consequent musculoskeletal, respiratory and cardiac complications, among others. Considering the high prevalence of this condition (Worldwide prevalence 0.5 per 10,000 men) (1,2) and the importance of multidisciplinary management for the timely diagnosis and proper management of patients, an interdisciplinary consensus of experts is made to propose recommendations for the diagnosis and follow up of Colombian patients with DMD.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Hoffman E, Brown RJ, Kunkel L. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51: p. 919-28.
Mah J, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014; 24(6): p. 482-91.
Mendell J, Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013; 48: p. 21-6.
Mendell J, Shilling C, Leslie N, Flanigan K, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 2012; 71: p. 304-13.
Gardner-Medwin D, Bundey S, Green S. Early diagnosis of Duchenne muscular dystrophy. Lancet. 1978; 1: p. 1102.
Emery A. The muscular dystrophies.. Lancet. 2002; 359: p. 687-95.
Patterson V, Morrison O, Hicks E. Mode of death in Duchenne muscular dystrophy. Lancet 1991. 1991; 337: p. 801-2.
Birnkrant D, Bushby K, Bann C, Apkon S, A B, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018; 17: p. 251-67.
Birnkrant D, Bushby K, Bann C, Apkon S, A B, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018; 17: p. 347-61.
Landfeldt E, Lindgren P, Bell C, Guglieri M, Straub V, Lochmüller H, et al. Health-related quality of life in patients with Duchenne muscular dystrophy: a multi-national, cross sectional study. Dev Med Child Neurol. 2016;58(5):508-15.. 2016; 58(5): p. 508-15.
Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9(1): p. 77-93.
Nascimento Osorio A, Medina Cantillo J, Camacho Salas A, Madruga Garrido M, Vilchez Padilla J. Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy.. Neurologia. 2018.
Dalkey N. Experimental Study of Group Opinion-Delphi Method. Futures. 1969; 1: p. 408-26.
Fink A, Kosecoff J, Chassin M, Brook R. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984; 74(9): p. 979-83.
Flanigan K. Duchenne and Becker muscular dystrophies.. Neurol Clin. 2014; 32(3): p. 671-88.
Guerra-Torres M, Suárez-Obando F, García-Robles R, Ayala-Ramírez P. Distrofia Muscular de Duchenne/Becker. Pediatr. 2019; 52(1): p. 8-14.
Aartsma-Rus A, Van Deutekom J, Fokkema I, Van Ommen G, Den Dunnen J. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006; 34(2): p. 135-44.
Monaco A, Bertelson C, Liechti-Gallati S, Moser H, Kunkel L. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2: p. 90-5.
García-Acero M, Pineda T, Guerra-Torres M, García-Robles R, Ayala-Ramírez P, Buitrago T, et al. Análisis del espectro mutacional de la distrofia muscular de Duchenne en un grupo de pacientes colombianos. Neurología Argentina. 2018; 10(3): p. 137-46.
Ervasti J, Campbell K. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 1993; 122: p. 809-23.
Petrof B. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol. Cell Biochem. 1998; 179: p. 111-23.
Giliberto F, Ferreiro V, Dalamon V, Szijan I. Dystrophin deletions and cognitive impairment in Duchenne/Becker muscular dystrophy. Neurol Res. 2004; 26(1): p. 83-7.
Brooke M, Fenichel G, Griggs R, Mendell J, Moxley R, Miller J, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the ‘‘power’’ of therapeutic trials based on the natural history. Muscle Nerve. 1983; 6: p. 91-103.
Nigro G, Comi L, Politano L, Bain R. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26:271-7. 1990; 26: p. 271-7.
Beck J, Weinberg J, Hamnegård C, Spahija J, Olofson J, Grimby G, et al. Diaphragmatic function in advanced Duchenne muscular dystrophy. Neuromuscul Disord. 2006; 16(3): p. 161-7.
Flanigan K. The Muscular Dystrophies. Semin Neurol. 2012; 32(03): p. 255-63.
Aartsma-Rus A, Hegde M, Ben-Omran T, Buccella F, Ferlini A, Gallano P, et al. Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy. J Pediatr. 2019; 204: p. 305-13.
Lalic T, Vossen R, Coffa J, Schouten J, Guc-Scekic M, Radivojevic D, et al. Deletion and duplication screening in the DMD gene using MLPA. Eur J Hum Genet. 2005; 13(11): p. 1231-4.
Silva C, Fonseca D, Restrepo C, Contreras N, Mateus H. Deleciones en el gen de la distrofina en 62 familias colombianas: correlación genotipo-fenotipo para la distrofia muscular de Duchenne y Becker. Colomb Med. 2004; 35: p. 191-8.
Wein N, Alfano L, Flanigan K. Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy. Pediatr Clin North Am. 2015; 62(3): p. 723-42.
Aartsma-Rus A, Ginjaar I, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016; 53(3): p. 145-51.
Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010; 9(2): p. 177-89.
Fenichel G, Florence J, Pestronk A, Mendell J, Moxley R, Griggs R, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991; 41(12):1874-7. 1991; 12: p. 1874-7.
Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur A. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016; 5: p. CD003725.
Markham L, Kinnett K, Wong B, Woodrow Benson D, Cripe L. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.. Neuromuscul Disord. 2008; 18(5): p. 365-70.
King W, Ruttencutter R, Nagaraja H, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007; 68(19): p. 1607-13.
Griggs R, Herr B, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve. 2013; 48(1):27-31. 2013; 48(1): p. 27-31.
Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve. 2012;45(6):796-802. 2012; 45(6): p. 796-802.
Pane M, Fanelli L, Mazzone E, Olivieri G, D’Amico A, Messina S, et al. Benefits of glucocorticoids in non- ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test. Neuromuscul Disord. 2015; 25(10): p. 749-53.
Gloss D, Moxley R, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016; 86(5): p. 465--72.
Kole R, Krieg A. Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev. 2015; 87: p. 104-7.
Syed Y. Eteplirsen: First global approval. Drugs. 2016; 76: p. 1699-704.
Rowel K, Lim Q, Maruyama R, Yokota T. Eteplirsen in 78. the treatment of Duchenne muscular dystrophy. Drug Design Development and Therapt. 2017; 11: p. 533-45.
Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi G, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014; 50: p. 477-87.
McDonald C, Henricson E, Abresch R, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013; 48(3): p. 343-56.
Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.. Physiother Res Int. 2012; 17(2): p. 101-9.
Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.. Neuromuscul Disord. 2010; 20(11): p. 712-6.
Bérard C, Payan C, Hodgkinson I, Fermanian J, Group MCS. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005; 15(7): p. 463-70.
McDonald C, Henricson E, Han J, Abresch R, Nicorici A, Elfring G, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010; 41(4): p. 500-10.
Mercuri E, Coratti G, Messina S, Ricotti V, Baranello G, D'Amico A, et al. Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS One. 2016; 11(8): p. e0160195.
de Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, Bérard C, et al. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013; 94(11): p. 2218-26.
de Lattre C, Payan C, Payet C, Fafin C, Girardot F, Jouve A. Motor function measure: construction of a short form (MFM-20) for children with neuromuscular disease aged between 2 and 6. Neuromuscul Disord. 2005; 19(8-9): p. 571.
Mayhew A, Mazzone E, Eagle M, Duong T, Ash M, Decostre V, et al. Development of the P erformance of the Upper Limb module for Duchenne muscular dystrophy. Developmental Medicine & Child Neurology. 2013; 55(11): p. 1038-45.
Pane M, Mazzone E, Fanelli L, De Sanctis R, Bianco F, Sivo S, et al. Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy.. Neuromuscul Disord. 2014; 24(3): p. 201-6.
Côté P, Kreitz B, Cassidy J, Dzus A, Martel J. A study of the diagnostic accuracy and reliability of the Scoliometer and Adam's forward bend test. Spine. 1998; 23(7): p. 796-802.
Rideau Y, Duport G, Delabeuir A, Guillou C, Renardel-Irani A, Bach J. Early treatment to preserve quality of locomotion for children with Duchenne muscular dystropy. Semin Neurol. 1995; 15: p. 9-17.
Smith S, Green N, Cole R, Robison J, Fenichel G. Prolongation of ambulation in children with Duchenne Muscular Dystrophy by sybcutaneous lower limb tenotomy. J Pediatr Orthop. 1993; 13: p. 336-40.
Heller K, Wirtz D, Siebert C, Forst R. Spinal stabilization in Duchenne muscular dystrophy: principles of treatment and record of 31 operative treated cases. J Pediatr Orthop. 2001; 10: p. 18-24.
McDonald D, Kinali M, Gallagher A, Mercuri E, Muntoni F, Roper H, et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol. 2002; 44: p. 695-8.
Buckner J, Bowden S, Mahan J. Optimizing bone health in Duchenne muscular dystrophy. Int J Endocrinol. 2015; 2015: p. 928385.
Tian C, Wong B, Hornung LKJ, Miller L, Bange J, Rybalsky I, et al. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016; 26(11): p. 760-7.
Mayer O, Finkel R, Rummey C, Benton M, Glanzman A, Flickinger J, et al. Characterization of pulmonary function in Duchenne Muscular Dystrophy. Pediatr Pulmonol. 2015; 50(5): p. 487-94.
Martínez Carrascoa C, Villa Asensib J, Luna Paredes M, Osona Rodríguez de Torres F, Peña Zarzad A, H LC, et al. Enfermedad neuromuscular: evaluación clínica y seguimiento desde el punto de vista neumológico. Anales de Pediatría. 2014; 81(4): p. 258.e1-17.
Finder J, Mayer O, Sheehan D, Sawnani H, Abresch R, Benditt J, et al. Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary. Am J Respir Crit Care Med. 2017; 196(4): p. 512-9.
Hoque R. Sleep-Disordered Breathing in Duchenne Muscular Dystrophy: An Assessment of the Literature. J Clin Sleep Med. 2016; 12(6): p. 905-11.
McNally E, Kaltman J, Benson D, Canter C, Cripe L, Duan D. Contemporary cardiac issues in Duchenne muscular dystrophy. Circulation. 2015; 131: p. 1590-8.
Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S. Nutritional Challenges in Duchenne Muscular Dystrophy. Nutrients. 2017; 10(9): p. pii: E594.
Griffiths R, Edwards R. A new chart for weight control in Duchenne muscular dystrophy. Arch Dis Child. 1988; 63(10): p. 1256-8.
Davis J, Samuels E, Mullins L. Nutrition Considerations in Duchenne Muscular Dystrophy.. Nutr Clin Pract. 2015; 30(4): p. 511-21.
West N, Yang M, Weitzenkamp D, Andrews J, Meaney F, Oleszek J, et al. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr. 2013; 163(6): p. 1759-63.
Toussaint M, Davidson Z, Bouvoie V, Evenepoel N, Haan J, Soudon P. Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management. Disabil Rehabil. 2016; 38(20): p. 2052-62.
van den Engel-Hoek L, de Groot I, de Swart B, Erasmus C. Feeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview. J Neuromuscul Dis. 2015; 2(4): p. 357-369.
Pangalila R. Quality of life in Duchenne muscular dystrophy: the disability paradox. Dev Med Child Neurol. 2016; 58(5): p. 435-6.
Uttley L, Carlton J, Woods H, Brazier J. A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. Health Qual Life Outcomes. 2018; 16(1): p. 237.
Donders J, Taneja C. Neurobehavioral characteristics of children with Duchenne muscular dystrophy. Child Neuropsychol. 2009; 15(3): p. 295-304.
Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, et al. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents.. J Child Neurol. 2011; 26(6): p. 707-13.
Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A, et al. Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy. J Child Neurol. 2015; 30(11): p. 1472-82.
Ricotti V, Mandy W, Scoto M, Pane M, Deconinck N, Messina S, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016; 58(1): p. 77-84.
Hendriksen J, Vles J. Neuropsychiatric disorders in males with Duchenne muscular dystrophy: Frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol. 2008 23 477-81.
Newborg J, Stock J, Wnek L. Batelle. Inventario de desarrollo. Tea. 2004.
Landfeldt E, Edström J, Buccella F, Kirschner J, Lochmüller H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018; 60(10): p. 987-96.
Landfeldt E, Lindgren P, Bell C, Guglieri M, Straub V, Lochmüller H, et al. Quantifying the burden of caregiving in Duchenne muscular dystrophy. J Neurol. 2016;263(5):906-915. 2016; 263(5): p. 906-15.
van Essen A, Mulder I, van der Vlies P, van der Hout A, Buys C, Hofstra R, et al. Detection of point mutation in dystrophin gene reveals somatic and germline mosaicism in the mother of a patient with Duchenne muscular dystrophy. Am J Med Genet A. 2003; 118A(3): p. 296-8.
Nozoe K, Akamine R, Mazzotti D, Polesel D, Grossklauss L, Tufik S, et al. Phenotypic contrasts of Duchenne Muscular Dystrophy in women: Two case reports. Sleep Sci. 2016 Jul-Sep; 9(3): 129–133.. 2016; 9(3): p. 129-33.